Skip to main content

Table 1 Liver biochemistry tests during follow up

From: Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients

Case Time to RE
(days)
Bilirubin
(mg/dL)
Albumin
(g/L)
AST
(U/L)
ALT
(U/L)
ALP
(U/L)
INR Ascites AFP
(μg/L)
1 −1 0.9 31 72 60 252 1.24a no 750
+12 1.2 30 75 51 326 minimal
+35 1.1 27 107 59 290 3.49a
+65 1.1 24 60 47 286 5.79a diffuse
+86 2.4 20 62 36 347 1.36a
2 −1 1.9 27 76 60 115 1.38 minimal 140
+14 4.3 25 96 58 138 moderate
+18 6.7 22 72 84 67 1.8 diffuse
+33 5.6 25 69 45 100 0.9 diffuse
+61 8.2 23 69 170 126 1.7 massive
+95 11.1 23 250 212 153 massive 36
3 0 1.6 25 61 46 122 1.18 minimal 270
+14 2.5 28 80 50 143 1.16 moderate 210
+30 2.3 22 58 32 126 1.20 moderate
+71 2.2 23 63 37 144 1.20 moderate
+160 2.9 23 67 32 156 1.20 massive 5200
  1. AFP alpha-fetoprotein, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio
  2. a = under treatment with coumarin derivates